Renalytix Plc (LON:RENX – Get Free Report) rose 22.4% during trading on Tuesday . The stock traded as high as GBX 2.50 and last traded at GBX 2.33. 3,694,300 shares changed hands during mid-day trading, an increase of 342% from the average session volume of 835,273 shares. The stock had previously closed at GBX 1.90.
Renalytix Stock Performance
The stock has a market capitalization of £10.16 million, a P/E ratio of -0.58 and a beta of 1.81. The company has a quick ratio of 2.42, a current ratio of 1.21 and a debt-to-equity ratio of -118.57. The company has a 50-day moving average price of GBX 1.81 and a two-hundred day moving average price of GBX 3.49.
Renalytix Company Profile
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
See Also
- Five stocks we like better than Renalytix
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
- These 3 Dividend Stocks Could Boost Your Income This July
- Rocket Lab Defies Gravity With $8B Buyout
- Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
